Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul 17;11(7):e7134.
doi: 10.1002/ccr3.7134. eCollection 2023 Jul.

A case of high-risk AML in a patient with advanced systemic mastocytosis

Manlio Fazio  1 , Calogero Vetro  2 , Uroš Markovic  2 , Andrea Duminuco  1 , Marina Parisi  2 , Cinzia Maugeri  2 , Elisa Mauro  2 , Nunziatina Laura Parrinello  2 , Fabio Stagno  2 , Loredana Villari  3 , Anna Maria Triolo  2 , Stefania Stella  4 , Giuseppe A Palumbo  1   5   6 , Francesco Di Raimondo  2   5 , Alessandra Romano  5 , Roberta Zanotti  7
Affiliations
Case Reports

A case of high-risk AML in a patient with advanced systemic mastocytosis

Manlio Fazio et al. Clin Case Rep. .

Abstract

Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine-venetoclax-midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.

Keywords: HAM regimen; advanced systemic mastocytosis (AdvSM); cladribine; concurrent hematologic disease; decitabine–venetoclax (DEC‐VEN); refractory acute myeloid leukemia (R‐AML).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they had no sources of funding for this study and no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

FIGURE 1
FIGURE 1
Immunohistochemical features of SM‐AHN (A–F). Photomicrograph of the bone marrow histology and immunohistochemistry supporting the diagnosis of SM‐AHN. SM and MDS/MPN: hypercellularity, granulocytic lineage expansion and paratrabecular infiltration of mast cells (MCs) (arrow) with the characteristic delicate fibrosis (arrowed), hematoxylin and eosin (H&E) stain (A); paratrabecular infiltration of MCs. The mast cell granules are well highlighted by the metachromatic staining with toluidine blue (B); cellularity predominantly determined by granulopoiesis expressing CD15 (C); positive immunostaining (brown) of spindle‐shaped MCs with CD 117 (D), CD25 (E), and tryptase (F). Morphology (G–I). AML: blasts and neutrophils (leukemic hiatus) (G, H). This PB smear was made after the first cycle of venetoclax and shows blast clearance with the persistence of pathologic spindle‐shaped MCs (in the picture) (I).
FIGURE 2
FIGURE 2
Graphs representing the trend of white blood cell count (A), platelet count (B), and tryptase level (C) from SM‐AHN diagnosis in 2017 until exitus in 2021. The graphs reflect the patient's measured platelet count (PLT), white blood cell count (WBC), and tryptase level after treatment with HU and H1/H2 antagonists, MDS/MPN evolution to AML and SM‐AML I and II line therapies. AML, acute myeloid leukemia; C, cycle; DEC, decitabine; D, day; GCSF, granulocyte colony‐stimulating factor; HU, hydroxyurea; MID, midostaurine; MLFS, morphologic leukemia‐free state; SM‐AHN, systemic mastocytosis with associated hematologic neoplasm; VEN, venetoclax.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200‐1228. - PMC - PubMed
    1. Valent P, Akin C, Sperr WR, et al. New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol. 2023;18(1):361‐386. - PubMed
    1. Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508‐525. - PubMed
    1. Valent P, Orazi A, Savona MR, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML). CMML Variants and Pre‐CMML Conditions. Vol 104. Haematologica. Ferrata Storti Foundation; 2019:1935‐1949. - PMC - PubMed
    1. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol. 2013;90:89‐98. - PMC - PubMed

Publication types